Our Recommendation

Showing posts with label fight. Show all posts
Showing posts with label fight. Show all posts

Wednesday, December 15, 2010

Reckless method to fight intestinal superbactérie (Seattle Post Intelligencer)

Last updated December 13, 2010 6: 34 PTBy LAURAN OBOLENSKY a.m.
AP medical writer photo this photo provided by the Centre Montefiore Medical taken Friday 10 December 2010, said Mr. Lawrence Brandt, Emeritus Chief of Gastroenterology, medical center in New York. He?s among a small but growing number of doctors to try a reckless effort against intestinal superbactérie transplanted someone healthy gut sick person?s stool. (AP Photo/Montefiore Medical Center)

WASHINGTON — a superbactérie named C-diff is on the rise, a germ that kind havoc tries intestines of some people who repeated the strongest, most expensive antibiotic can conquer their disabling diarrhea.

Now a small but growing number of physicians seeking a reckless treatment: for good bacteria to fight the evil by transplantation of stool a person healthy colon of the ill person.

Yes, there is a factor. But reports of several dozen in a medical journal and a meeting of gastroenterologists nation fall suggest with any disadvantage more colonoscopy, people who have suffered from C-diff for months or more, can rapidly improve.

"This is the ultimate probiotic,", explains Dr. Lawrence Brandt New York Montefiore Medical Center, who conducted 17 procedures.

However, it is much more complex: a bacterial neighbourhood full is transplanted, almost like less than organ transplantation anti-rejection drugs, says Mr. Alexander Khoruts, University of Minnesota. He took a DNA from bacteria of the digestive tract in a woman left emaciated after eight months of serious C-origin not only did disappear from the diarrhoea after faecal transplant, but that the normal bacteria mirroring husband - donor - quickly took root in his gut recovery.

Here's warning: fecal transplants have not studied in the way that science needs to prove that they work - by comparing similar patients graft or more intense antibiotics. History is filled with treatment failures as promising raw physicians in a real test until they were submitted.

"Nothing very good reasons to believe this faecal transplant or bacteriotherapy, may work, but it must be proven before everyone starts to do," says Mr. Lawrence Schiller, a gastroenterologist in Dallas Baylor health care system. Follow-up reports on the American College of the recent meeting of Gastroenterology treatment, but has not joined the emerging trend.

C diff, officially called Clostridium difficile, became a threat in hospitals across the country and can spread outside of one of them, too. Some patients suffer from diarrhea just benign, but others, especially older weakened by the previous disease can develop a more serious condition called colitis. There aren't accurate counts in the indictment, but some Government estimates suggest as c-diff may be responsible for up to 15 000 deaths per year.

Up to one-third of patients experience a second infection, and some will suffer recurrent episodes. Worst patients are placed on more powerful doses of antibiotics Vancomycin for weeks, even months at a time, treatments that Brandt, explains can cost $ 2,500 or with each attempt.

But because antibiotics kill so good and bad germs, C-diff can bounce to a now exhausted colon hundreds of species of bacteria that are supposed to live there.

"They are caught in the cycle of treatment and reprocessing," explains Khoruts Minnesota conducted grafts fecal 21 since discovering how normal bacteria has included in its first patient in 2008. He now began more detailed before - and after mapping of patients to try to determine if special bacteria are essential.

Faecal transplant are new step - the first was reported in 1958, and they performed occasionally since. But 170 cases described in medical journals since then, approximately one-third have been published this year, suggesting increased interest in the problem of C-diff grows, said Brandt at Montefiore.

The doctors who practise transplantation of faeces agree that more rigorous research is needed - without it, there is no way of knowing if only supposed success and not failures are written. Brandt provides a pilot study.

"I used to say it is just a measure of patient how desperate and their doctors." ' There came a time when there was nothing else to do, ", explains Dr. Christina Surawicz Harborview Medical Center at the University of Washington to conduct its 16th procedure last week.

How they are doing? There is not a method. Brandt insists on a list of tests to ensure that the donor has no diseases such as hepatitis or HIV or intestinal parasites. And then the donor, usually a close parent, brings a fresh stool that liquefies and drips mainly in the colon for colonoscopy Brandt routine patient sample.

Insurance companies do specifically cover faecal transplant, but they pay colonoscopies for patients to C-diff, Brandt, explains. Donor test can be run to several hundred dollars. If the insurance does not cover it, patients pay.

One patient Brandt has undergone recurrent episodes of C-diff for about 18 months to find the option. "You start to look like a leper," said honestly, Ruth, a woman in New York, who asked that his name be not used. She said that she felt great two years since graduation of treaties, while "I'll tell you that I did not take another antibiotic."

---

NOTE for the editorial - Lauran Neergaard covers medical and health for the Associated Press problems in Washington.

Sunday, December 12, 2010

How natural medicines, Abscisic acid, fight against inflammation (science daily)

PharmaLive.com (9 December 2010) - Virginia Tech Virginia bioinformatics Institute researchers have discovered how Abscisic acid, a natural plant hormone with beneficial properties for the treatment of the disease, help fight inflammation. The results, published in November 2010 Journal of Biological Chemistry, reveal the new important for the development of treatments for inflammatory and immune disease drug targets.

Scientists reported some of the major molecular events in the immune system of mice that contribute to disease associated with inflammation, including the participation of a specific molecule found on the surface of immune cells involved in fight against infection. They now have to go a little further and revealed the mechanism by which acid Abscisic natural drug interacts with this protein called receiver activated by peroxisome-gamma, block inflammation and the subsequent emergence of disease.

"In previous work, our research group demonstrates that beneficial on several conditions and diseases, including obesity, diabetes, atherosclerosis and inflammatory bowel disease-related inflammation Abscisic acid, said Josep Bassaganya-Riera, Professor of Immunology at the Institute of bioinformatics in Virginia, leader of the group medical researcher and Molecular Immunology nutrition and CyberInfrastructure Institute Division principal study." An idea of how Abscisic acid reduces inflammation in these cases, it is that it binds to a particular region of activated by peroxisome proliferator gamma receptor binding site called where the drug should lock to exert its effect ligand binding domain. Our results show that this is not the case and, for the first time, we have demonstrated that Abscisic acid works independently of this receptor ligand binding domain. »

"This information is important because it suggests the existence of new therapeutic targets or other modes of action that take into account the effects of Abscisic acid in the immune system," added Bassaganya-Riera. "Drugs that bind to the domain binding of the ligand peroxisome proliferator activated receptor gamma as Avandia are associated with serious cardiovascular side effects". However, the newly discovered alternative peroxisome mechanism activated by activation of the receptor gamma by Abscisic acid does not appear to be linked to any undesirable side effects known as representing a promising new therapy. »

"This search results illustrate the synergy which may result from combining experimental and computational approaches to characterizing the therapeutic targets," said David Bevan, Professor of Biochemistry at Virginia Tech "by using molecular modeling approaches we could identify a potential site of Abscisic acid on 2 protein binding C resembling lanthionine synthetase, a protein required for the beneficial effects of the health of Abscisic acid." We also have, studies, mooring to reveal the reasons for the absence of a direct association of Abscisic acid with peroxisome activated receptor gamma has been experimentally validated by the ligand binding assays. »

"Lanthionine synthetase 2 C-like represents the first step in a path leading to activation of peroxisome proliferator-activated receptor gamma in immune cells by Abscisic acid," said Raquel Hontecillas, Professor of Immunology at the Virginia bioinformatics Institute and one of the researchers of the study lead. "We have shown as Abscisic acid affects the expression of several genes involved in inflammation, metabolism and cell signaling, which provides clues to possible points of intervention for the treatment of inflammatory and immune diseases."

Researchers hope more closely to locate some of the new drug targets in molecular immune response network continue to dissect the way that the drug naturally Abscisic acid reduces damage due to inflammation. In addition, the memorandum of understanding on novel how Abscisic acid works used to develop new classes of drugs that target the same way alternative activation of gamma receptors activated by peroxisome proliferator, potentially safer than the use of drugs that directly target receptor binding approach.

The research was funded by 5R01AT004308 number award by the National Center for Complementary and Alternative Medicine at the National Institutes of Health, European Commission grant number 224836, the program of Ramon y Cajal, National Institute of Allergy and infectious diseases Contract No.. HHSN272200900040C, National Institute of Allergy and infectious diseases HHSN272201000056C contract and nutritional immunology Fund and the laboratory of molecular medicine.

Warning: this article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those PharmaLive.com or its staff.

Source of the story:

The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Virginia Tech, via EurekAlert!, a service of AAAS.

Reference of the review:

Bassaganya Riera J, Guri AJ, Lu P, M Climent, Carbo, Sobral BW, Horne WT, Lewis SN, DR Bevan, r. Hontecillas of Abscisic acid regulates inflammation through the activation of the independent from the PPAR {gamma} field ligand binding. J Biol Chem. 2010, 18 November 2010 [link]

Note: If no author is given, the source is cited for this.

Trio of drugs may fight "triple negative" cancer (science daily)

PharmaLive.com (December 10, 2010) - resistance to medicines, a cocktail of triple-drug for breast cancer gene target triple negative and the risk of carpal tunnel syndrome patients are among the points highlights study to be presented by researchers at the Johns Hopkins Kimmel Cancer Center at the 33rd Annual CTRC - AACR San Antonio Cancer Symposium, held from 8 to 12 December.

In collaboration with cell cultures and mice models, researchers at the Johns Hopkins Kimmel Cancer Center have tested a cocktail of three promising drugs for the treatment of what is known as triple negative cancer.

Women with these cancers are missing hormone receptor 3 - estrogen and progesterone and human epidermal growth factor 2 (HER2). Currently, the triple negative breast cancers treatments are limited to surgery, chemotherapy and radiotherapy, which provide some improvements, but overall prognosis.

In the new study, scientists at the Johns Hopkins University has begun with a drug called Entinostat, blocks the enzyme that happens to make regulatory genes in the DNA molecules and reactivates a gene called Retinoic acid receptor beta (RARß). Then they have added a drug called all Trans Retinoic acid (Alliance), linked to vitamin A, which binds to a protein made by the reactivated RARß gene. Overall, drug Alliance and gene RARß act as an impediment to the growth of cancer cells. Scientists completed the cocktail of drugs by conventional chemotherapy in low doses of doxorubicin or paclitaxel.

According to scientists, each of the three drugs used alone may have an effect on the Elimination of tumor cells but by combining tips the scale in favour of the Elimination of cells more.

Cells grown in laboratory tests have shown that triple therapy from the drop-down list box stopped the growth of multiple triple negative breast cancer cell lines more effectively as one of the only treatments. The combination therapy also rejuvenated RARß expression and strongly inhibited tumor growth in all three quarters mice grafted with breast tumor cells.

Researchers discuss potential clinical trials of the drop-down list box therapy hoping to start next year, says Nguyen k. Nguyen, a graduate student in cellular and molecular medicine at the Johns Hopkins University program.

Warning: this article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those PharmaLive.com or its staff.

Source of the story:

The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Johns Hopkins Medical Institutions, via EurekAlert!, a service of AAAS.

Note: If no author is given, the source is cited for this.

Saturday, December 11, 2010

Trio of drugs may fight "triple negative" cancer (science daily)

PharmaLive.com (December 10, 2010) - resistance to medicines, a cocktail of triple-drug for breast cancer gene target triple negative and the risk of carpal tunnel syndrome patients are among the points highlights study to be presented by researchers at the Johns Hopkins Kimmel Cancer Center at the 33rd Annual CTRC - AACR San Antonio Cancer Symposium, held from 8 to 12 December.

In collaboration with cell cultures and mice models, researchers at the Johns Hopkins Kimmel Cancer Center have tested a cocktail of three promising drugs for the treatment of what is known as triple negative cancer.

Women with these cancers are missing hormone receptor 3 - estrogen and progesterone and human epidermal growth factor 2 (HER2). Currently, the triple negative breast cancers treatments are limited to surgery, chemotherapy and radiotherapy, which provide some improvements, but overall prognosis.

In the new study, scientists at the Johns Hopkins University has begun with a drug called Entinostat, blocks the enzyme that happens to make regulatory genes in the DNA molecules and reactivates a gene called Retinoic acid receptor beta (RARß). Then they have added a drug called all Trans Retinoic acid (Alliance), linked to vitamin A, which binds to a protein made by the reactivated RARß gene. Overall, drug Alliance and gene RARß act as an impediment to the growth of cancer cells. Scientists completed the cocktail of drugs by conventional chemotherapy in low doses of doxorubicin or paclitaxel.

According to scientists, each of the three drugs used alone may have an effect on the Elimination of tumor cells but by combining tips the scale in favour of the Elimination of cells more.

Cells grown in laboratory tests have shown that triple therapy from the drop-down list box stopped the growth of multiple triple negative breast cancer cell lines more effectively as one of the only treatments. The combination therapy also rejuvenated RARß expression and strongly inhibited tumor growth in all three quarters mice grafted with breast tumor cells.

Researchers discuss potential clinical trials of the drop-down list box therapy hoping to start next year, says Nguyen k. Nguyen, a graduate student in cellular and molecular medicine at the Johns Hopkins University program.

Warning: this article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those PharmaLive.com or its staff.

Source of the story:

The story above is reproduced (with drafting adaptations by staff at PharmaLive.com) materials provided by Johns Hopkins Medical Institutions, via EurekAlert!, a service of AAAS.

Note: If no author is given, the source is cited for this.